Along with the upfront payment, Teva is in line for up to €940 million ($990 million) in milestone payments, with the two companies sharing development costs. TL1A or tumour necrosis factor-like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback